BriaCell declares ImaginAb’s CD8 ImmunoPET ‘the Holy Grail’ in looking at tumor infiltrating lymphocytes in a non-invasive way and removing the need for uncomfortable and painful biopsies
Dr William V. Williams BriaCell’s President & CEO, in a recent interview with SmallCapVoice announced he was “very excited to be working with ImaginAb”.
The announcement follows the news in August that BriaCell and ImaginAb will collaborate to evaluate immunotherapy imaging technology in advanced breast cancer. In the interview, Dr Williams highlighted that ImaginAb’s CD8 ImmunoPET is “extremely interesting technology”.
CD8 ImmunoPET allows whole body visualization of CD8 T cells, including increased infiltration of CD8 cells in tumors after treatment. CD8 imaging provides early insight into drug performance, patient response, and clinical outcomes. BriaCell will use the technology to determine whether Bria-IMT(tm), their cellular immunotherapy for breast cancer, can elicit T cell infiltration into breast cancer tumors in a safe and effective way.
If you would like to know more about how CD8 ImmunoPET technology can revolutionize the immuno-oncology patient care path then contact us at: firstname.lastname@example.org
“Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reducing the length of trials and allowing new therapies to advance to market quicker. It also removes the need for repeat, painful biopsies, all of which could ultimately transform patient care.
We are delighted that BriaCell recognize the potential that our technology offers and look forward to working closely with them as they use it to image the response of breast cancer to their novel targeted immunotherapy treatment”